晚期非小细胞肺癌RRM1表达与吉西他滨疗效的相关性分析  

Analysis of RRM1 Expression and Efficacy of Gemcitabine in Advanced Non-small Cell Lung Cancer

作　　者：江波[1,2] 涂长玲[1,2] 何文杰[1,2] 杨承纲[1,3] 赵金奇[1,2] 

机构地区：[1]昆明医科大学第三附属医院 [2]云南省肿瘤医院干部医疗科,昆明650118 [3]云南省肿瘤医院病理科,昆明650118

出　　处：《肿瘤防治研究》2013年第1期68-71,共4页Cancer Research on Prevention and Treatment

基　　金：云南省教育厅科学基金资助项目(2010Y183)

摘　　要：目的探讨晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)组织中核苷酸还原酶M1(RRM1)的表达水平与吉西他滨联合顺铂化疗疗效及预后的相关性。方法通过免疫组织化学法检测60例晚期NSCLC患者肺组织中RRM1蛋白表达水平,并与患者的临床特征、吉西他滨联合顺铂化疗的疗效及预后的关系进行分析。结果 RRM1的表达在不同性别间差异有统计学意义(P<0.05);在不同年龄、组织学类型及分期间差异无统计学意义(P>0.05)。RRM1低表达组的化疗有效率(57.7%)及疾病控制率(69.2%)均高于高表达组(29.4%,35.3%)(P<0.05)。在对生存期的分析中发现RRM1低表达组的生存期(18月)及无疾病进展期(6月)均明显长于高表达组(13月,4月)(P<0.05),1年生存率(69.2%)及2年生存率(23.1%)均高于高表达组(58.8%,3%)(P<0.05)。结论晚期非小细胞肺癌组织中RRM1低表达的患者对吉西他滨联合顺铂化疗反应的有效率更高,生存期更长,是独立的预后因素。这将有助于筛选适合接受吉西他滨联合顺铂进行一线化疗的患者。Objective To investigate the clinical efficacy and prognostic significance of ribonucleotide reductase MI （RRM1） expression in lung tissue of patients with Non-small cell lung eancer（NSCLC） treated with gemcitabine combined with＂ platinum. Methods Tumor samples obtained from 6（1 patients with advanced NSCLC were collected to investigate the expression level of RRM1 by the immunohisto chemical methods. Relationships between the expression and clinical characters, efficacy, overall survival time of patients with advanced NSCLC were analyzed. Results The RRM1 expression was significant difference between male and female（P〈0.05） ,while there was no correlation between RRMI expression and age,pathological type and TNM stage（P〉0. 05）. Patients with low expression had remarkably high- er response rate（57.7%） and disease control rate（69. 2%） to gemcitabine than overexpression RRMI group（ 29. 4%,35. 3%） （P〈0. 05）. Low expression group of RRM1 had longer overall survival（IS months,13 months）,longer progression free survival（6months,4months） and higher 1-year survival rate （69.2%,58.8%）,2 year survival rate（（23. 1%,3%） than over expression group（P〈0. 05）. Conclusion The patients with low RRM1 expression levels have higher response to chemotherapy and longer survival time. RRM1 expression is an independent prognostic factor. The result of this study may be helpful for selecting patients of advanced NSCLC with low RRM1 expression levels to accept gemcitabine combined with platinum.

关 键 词：非小细胞肺癌 核苷酸还原酶M1 吉西他滨 疗效 免疫组织化学 

分 类 号：R734.2[医药卫生—肿瘤]